Emotion regulation is a core transdiagnostic process in mood, anxiety, and stress-related disorders. While existing non-invasive brain stimulation approaches, such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), can modulate affective networks, their clinical use is limited by restricted spatial precision and depth penetration. Transcranial focused ultrasound stimulation (tFUS) offers submillimeter focality and access to both cortical and deep subcortical structures, making it a promising tool for affective neuromodulation. We systematically searched PubMed, Embase, and PsycINFO for human studies using tFUS to modulate emotion regulation, affective processing, or related symptoms. Eligible studies included randomized controlled trials (RCTs), open-label, and within-subject designs. Data on stimulation parameters, target regions, outcomes, and safety were extracted. Effect sizes were calculated and pooled using a random-effects model, with subgroup analyses by clinical domain. Eleven studies met inclusion criteria, targeting the amygdala ( n = 5), prefrontal cortex (n = 5), or subcallosal cingulate cortex ( n = 1), with protocols varying in frequency (250–650 kHz), duty cycle (0.5–70%), and number of sessions (1–25). Across six studies reporting behavioral symptom outcomes, the pooled effect was moderate-to-large (Hedges' g = 0.88, 95% CI 0.47, 1.29), with larger effects in depression-related measures (g = 1.31) than in anxiety-related measures (g = 0.67). Imaging outcomes were reported in a smaller subset of studies and were not included in the pooled estimates. No serious adverse events were reported. tFUS is a safe and well-tolerated intervention capable of engaging deep affective circuits; however, quantitative estimates remain preliminary given the small and heterogeneous evidence base. Future large-scale, harmonized, and mechanistically informed trials are warranted to refine protocols, establish durability, and optimize translation into clinical practice. • Eleven human studies targeting amygdala, prefrontal cortex, or subcallosal cingulate • Moderate-large symptom benefits overall (Hedge's g = 0.88); no serious adverse events • Larger effects in depressive-related measures (g = 1.31) than anxiety-related measures (g = 0.67) • Protocols varied widely; harmonized, sham-controlled trials are needed.
Kang et al. (Sun,) studied this question.